Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Chiesi Farmaceutici acquires Amryt Pharma to bolster access to rare disease therapies

By Brian Buntz | April 12, 2023

Chiesi/AmrytChiesi Farmaceutici, a family-owned international pharma company, has completed its $1.25 billion acquisition of rare disease-focused biopharma Amryt Pharma (Nasdaq:AMYT). The companies announced the deal in January and projected it would close in the first half of 2023.

Strengthening Chiesi’s global rare disease focus

Chiesi’s decision to acquire Amryt Pharma is part of a broader trend of increased M&A activity in the pharma sector. In the first few months of  2023, Pfizer, Sanofi, AstraZeneca, and Amgen have also announced significant acquisition plans.

The Chiesi acquisition aims to strengthen Chiesi’s Global Rare Diseases business division. Amryt Pharma’s product portfolio includes three approved commercial products:

  • Lojuxta/Juxtapid (lomitapide) for treating homozygous familial hypercholesterolemia. This condition involves high levels of low-density lipoprotein cholesterol (LDL-C) in the blood, contributing to premature cardiovascular disease and atherosclerosis. Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor.
  • Myalept/ Myalepta (metreleptin) for generalized lipodystrophy. A recombinant analog of human leptin, metreleptin treats subtypes of lipodystrophy, a group of rare disorders characterized by the loss or lack of fat tissue.
  • Mycapssa (octreotide) for acromegaly. Octreotide is a synthetic somatostatin analog that mimics the inhibitory actions of the natural hormone somatostatin, playing a role in various physiological processes, such as secreting growth hormone, insulin, and glucagon.
    Pipeline product under regulatory review

Amryt’s lead pipeline product, Oleogel-S10 (Filsuvez), is currently under regulatory review in the U.S. and E.U. for treating epidermolysis bullosa.

How Chiesi aims to harness Amryt’s product portfolio for rare diseases

Expanding its reach in rare diseases, Chiesi Global Rare Diseases plans to tap Amryt’s product portfolio and pipeline for various conditions, such as Leber’s hereditary optic neuropathy, nephropathic cystinosis, alpha-mannosidosis, thalassemia, sickle cell disease, ADA-SCID and Fabry disease .

Chiesi Farmaceutici is a certified B Corp, a measure of social and environmental performance, transparency, and accountability. The company’s B Corp status will likely influence the integration of Amryt Pharma, focusing on patient-centric and sustainable practices.

The company noted in a press release that it would work to ensure that Amryt Pharma’s operations align with its mission and values. This includes prioritizing patient access to treatments, implementing sustainable business practices, and encouraging transparency in reporting and communication.

Chiesi’s recent regulatory win with Lamzede

Earlier this year, Chiesi Farmaceutici achieved a regulatory win in the U.S. with Lamzede (velmanase alfa), an enzyme replacement therapy acquired in its 2013 acquisition of Zymenex. The FDA approved the drug for treating non-central nervous system manifestations of alpha-mannosidosis (AM), an ultra-rare, progressive lysosomal storage disorder. Lamzede is the first enzyme replacement therapy for this inherited condition. The drug’s indication covers both adults and children.


Filed Under: Rare disease
Tagged With: acquisition, Amryt Pharma, B Corp, biopharmaceutical, Chiesi Global Rare Diseases, Rare Diseases
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Novartis in the Pharma 50
Novartis announces positive phase 3 data for intrathecal gene therapy in older SMA patients
Deep Genomics
Deep Genomics announces key hires, expands operations in Cambridge, Mass.
DNA matrix image
From Novartis to Pfizer: A closer look at novel cell and gene therapy pricing and reimbursement strategies
Dividing cancer cells - 3D illustration
FDA approves pair of therapies for rare pediatric cancers: Novartis’ Lutathera and Day One’s Ojemda
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE